Ben Barak Ayelet, Golan Hana, Waldman Dalia, Arkovitz Marc S
Department of Pediatric Oncology, Rambam Medical Center, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Department of Pediatric Oncology, Sheba Medical Center, Tel Hashomer, Israel.
Isr Med Assoc J. 2017 Nov;19(11):691-695.
Neuroblastoma is the most common non-central nervous system (CNS) solid malignant tumor in children. The surgical treatment of high-risk neuroblastoma presents a challenge, and the benefits of aggressive surgical resection have been called into question.
To examine our experience with surgical resection of neuroblastoma.
We report on a retrospective chart review of our preliminary surgical experience in 25 patients with neuroblastoma who underwent surgery performed by a single surgeon at two institutions over a 3 year period. Demographic data, including stage of tumor and risk stratification, were recorded. Primary outcome was total gross resection. Patients were followed for 3 years after surgery.
We found that 80% of the patients, including those with high-risk neuroblastoma tumors, had total gross resection of their tumor with minimal operative morbidity and no mortality; 88% had greater than 90% resection of their tumor. Overall, 3 year survival was 84% (21/25).
Resection of neuroblastoma, even large, high-risk, bilateral tumors, was possible when performed by surgical teams with considerable experience.
神经母细胞瘤是儿童最常见的非中枢神经系统（CNS）实体恶性肿瘤。高危神经母细胞瘤的外科治疗具有挑战性，积极手术切除的益处也受到质疑。
探讨我们在神经母细胞瘤手术切除方面的经验。
我们报告了一项回顾性病历审查，内容是一名外科医生在两家机构3年期间对25例神经母细胞瘤患者进行手术的初步经验。记录了人口统计学数据，包括肿瘤分期和风险分层。主要结局是肿瘤全切除。患者术后随访3年。
我们发现，80%的患者，包括那些患有高危神经母细胞瘤肿瘤的患者，实现了肿瘤全切除，手术并发症极少且无死亡；88%的患者肿瘤切除率超过90%。总体而言，3年生存率为84%（21/25）。
由经验丰富的手术团队进行神经母细胞瘤切除，即使是大型、高危、双侧肿瘤也是可行的。
